Defense Advanced Research Projects AgencyTagged Content List

Chemistry

The identification and transformation of substances

Showing 5 results for Chemistry + Disease RSS
06/12/2020
Antibiotic resistance is on the rise and is recognized by both the CDC1 and the U.S. Military2 as a current – and formidable – global health threat. The U.S Department of Defense (DoD) has long documented the warfighter’s outsized risk of exposure to infectious disease, including the increasing number of multi-drug resistant (MDR) organisms that have challenged military wound care in Iraq and Afghanistan3. Despite this looming crisis, there has been a notable exodus of pharmaceutical companies from the antibiotic space, as well as several high-profile failures of biotechnology companies focused on antibiotic development4.
Microbial infections are a problem of particular concern to the Department of Defense (DoD). The DoD has long recognized the warfighter’s outsized risk of exposure to infectious disease, including the rise of antimicrobial resistant (AMR) and multidrug resistant (MDR) pathogens that have challenged military wound care in Iraq and Afghanistan. Furthermore, the responsibility of the DoD to protect the homeland encompasses biological threat agents, including bacterial threats, for which effective countermeasures are critical.
Program Manager
Dr. Amy Jenkins joined DARPA as a program manager in the Biological Technologies Office (BTO) in June 2019. Her interests include the development of platforms for combatting infectious disease threats as well as novel manufacturing methods to enable rapid response.
Office Director
Dr. Brad Ringeisen was named Office Director of BTO in June 2019. He joined DARPA as the deputy director of BTO in December 2016.
Program Manager
Dr. Seth Cohen joined DARPA as a Program Manager in August 2019. He is interested in novel materials, new approaches to therapeutics/countermeasures, and biological and chemical technologies for stabilization/acquisition of scarce resources.